Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites?

Case Reports in Gastroenterology

Volumn 6, Issue 1, 2012, Pages 166-170

  De Mestier, Louis ^a   Volet, Julien ^a   Scaglia, Elodie ^a   Msika, Simon ^b   Kianmanesh, Reza ^a,b   Bouché, Olivier ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b HÔPITAL LOUIS MOURIER   (France)

Author keywords

Ascites; Cancer; Hemoperitoneum; Hyperthermic intraperitoneal chemotherapy; Intraperitoneal drug delivery; Laparoscopy; Palliative surgery

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; EVEROLIMUS; FLUOROURACIL; MITOMYCIN C; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CASE REPORT; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; MALE; MALIGNANT ASCITES; MALIGNANT HEMORRHAGIC ASCITES; MULTIPLE CYCLE TREATMENT; OPERATION DURATION; PRIORITY JOURNAL; QUALITY OF LIFE; RETROPERITONEAL HEMORRHAGE; STOMACH BIOPSY;

EID: 84860755411     PISSN: None     EISSN: 16620631     Source Type: Journal    
DOI: 10.1159/000338070     Document Type: Article

References (11)

1. Adam RA, Adam YG: Malignant ascites: past, present, and future. J Am Coll Surg 2004;198:999-1011.
2. Ayantunde AA, Parsons SL: Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007;18:945-949.
3. Becker G, Galandi D, Blum H: Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006;42:589-597.
4. Garofalo A, Valle M, Garcia J, Sugarbaker PH: Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 2006;32:682-685.
5. Facchiano E, Scaringi S, Kianmanesh R, et al: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 2008;34:154-158.
6. McQuellon RP, Loggie BW, Fleming RA, et al: Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65-73.
7. Valle M, van der Speeten K, Garofalo A: Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 2009;100:331-334.
8. Ba MC, Cui SZ, Lin SQ, et al: Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol 2010;16: 1901-1907.
9. Roviello F, Caruso S, Marrelli D, et al: Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol 2011;20:38-54.
10. Heiss MM, Murawa P, Koralewski P, et al: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-2221.
11. El-Shami K, Elsaid A, El-Kerm Y: Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol 2007;25(suppl 18): abstract 9043.